Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field

Journal of Infectious Diseases

Volumn 213, Issue 1, 2016, Pages 6-13

  Poolman, Jan T ^a   Wacker, Michael ^b  

^a Janssen Research and Development   (Netherlands)

^b GlycoVaxyn AG   (Switzerland)

Author keywords

Escherichia coli; extraintestinal pathogenic Escherichia coli; vaccine; O antigen; disease burden; antimicrobial resistance; urinary tract infection

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BACTERIAL PROTEIN; CEPHALOSPORIN; ESCHERICHIA COLI VACCINE; EXOPROTEIN A; EXTRAINTESTINAL PATHOGENIC ESCHERICHIA COLI VACCINE; LIPOPOLYSACCHARIDE; O ANTIGEN; PGLB PROTEIN; POLYSACCHARIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRANSFERASE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; DRUG CONJUGATION; DRUG EFFICACY; EPIDEMIC; ESCHERICHIA COLI INFECTION; EXTRAINTESTINAL PATHOGENIC ESCHERICHIA COLI; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; MOLECULAR TYPING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; URINARY TRACT INFECTION; VACCINE PRODUCTION; ESCHERICHIA COLI;

DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; HUMANS; O ANTIGENS; URINARY TRACT INFECTIONS;

EID: 84961990781     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv429     Document Type: Article

References (49)

1. Russo TA, Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect Inst Pasteur 2003; 5: 449-56
2. Mathers AJ, Peirano G, Pitout JD. Escherichia coli ST131: the quintessential example of an international multiresistant high-risk clone. Adv Appl Microbiol 2015; 90: 109-54
3. Cross A, Artenstein A, Que J, et al. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis 1994; 170: 834-40
4. Orskov F, Orskov I. Escherichia coli serotyping and disease in man and animals. Can J Microbiol 1992; 38: 699-704
5. Stenutz R, Weintraub A, Widmalm G. The structures of Escherichia coli O-polysaccharide antigens. FEMS Microbiol Rev 2006; 30: 382-403
6. Vahlne G. Serological typing of the colon bacteria, with special reference to the occurrence of B. coli in man under normal and pathological conditions, particularly in appendicitis. Acta Path Microbiol Scand 1945; 62: 1
7. Sjostedt S. Pathogenicity of certain serological types of B. coli: their mouse toxicity, hemolytic power, capacity for skin necrosis and resistance to phagocytosis and bactericidal faculties of human blood. Acta Path Microbiol Scand 1946; 63: 1
8. Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem 2006; 75: 39-68
9. Geue L, Monecke S, Engelmann I, Braun S, Slickers P, Ehricht R. Rapid microarray-based DNA genoserotyping of Escherichia coli. Microbiol Immunol 2014; 58: 77-86
10. Edelsberg J, Weycker D, Barron R, et al. Prevalence of antibiotic resistance in US hospitals. Diagn Microbiol Infect Dis 2014; 78: 255-62
11. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 2014; 28: 1-13
12. Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol 2013; 34: 940-6
13. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34: 1-14
14. Schmiemann G, Gágyor I, Hummers-Pradier E, Bleidorn J. Resistance profiles of urinary tract infections in general practice-an observational study. BMC Urol 2012; 12: 33
15. Laupland KB, Church DL. Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev 2014; 27: 647-64
16. De Kraker ME, Jarlier V, Monen JC, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect 2013; 19: 860-8
17. Jackson LA, Benson P, Neuzil KM, Grandjean M, Marino JL. Burden of community-onset Escherichia coli bacteremia in seniors. J Infect Dis 2005; 191: 1523-9
18. Rudzinski JK, Kawakami J. Incidence of infectious complications following transrectal ultrasound-guided prostate biopsy in Calgary, Alberta, Canada: a retrospective population-based analysis. Can Urol Assoc J 2014; 8: E301-5
19. Liss MA, Johnson JR, Porter SB, et al. Clinical and microbiological determinants of infection after transrectal prostate biopsy. Clin Infect Dis 2015; 60: 979-87
20. Williamson DA, Lim A, Wiles S, Roberts SA, Freeman JT. Population-based incidence and comparative demographics of community-associated and healthcareassociated Escherichia coli bloodstream infection in Auckland, New Zealand, 2005-2011. BMC Infect Dis 2013; 13: 385
21. Roubaud Baudron C, Panhard X, Clermont O, et al. Escherichia coli bacteraemia in adults: age-related differences in clinical and bacteriological characteristics, and outcome. Epidemiol Infect 2014; 142: 2672-83
22. Elixhauser A, Friedman B, Stranges E. Septicemia in U.S. Hospitals, 2009. Statistical brief 122. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Health Care Policy and Research, 2006. http://www. ncbi.nlm.nih.gov/books/NBK65391/. Accessed 27 January 2015
23. Søgaard M, Nørgaard M, Dethlefsen C, Schønheyder HC. Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: a population-based cohort study. Clin Infect Dis 2011; 52: 61-9
24. Schlackow I, Stoesser N, Walker AS, et al. Increasing incidence of Escherichia coli bacteraemia is driven by an increase in antibiotic-resistant isolates: electronic database study in Oxfordshire 1999-2011. J Antimicrob Chemother 2012; 67: 1514-24
25. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), 2012. http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012. pdf. Accessed 26 December 2014
26. Niranjan V, Malini A. Antimicrobial resistance pattern in Escherichia coli causing urinary tract infection among inpatients. Indian J Med Res 2014; 139: 945-8
27. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance Chaired by Jim O Neill, 2014. http://www.his.org.uk/files/4514/1829/6668/AMR-Review-Paper-Tackling-a-crisis- for-the-health-and-wealth-of- nations-1.pdf. Accessed 26 December 2014
28. Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL. Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis 2013; 57: 267-74
29. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379-86
30. Tchesnokova V, Billig M, Chattopadhyay S, et al. Predictive diagnostics for Escherichia coli infections based on the clonal association of antimicrobial resistance and clinical outcome. J Clin Microbiol 2013; 51: 2991-9
31. Johnson JR, Clermont O, Johnston B, et al. Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within Escherichia coli sequence type 131. J Clin Microbiol 2014; 52: 1358-65
32. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. Coli infections in the United States. Clin Infect Dis 2010; 51: 286-94
33. Banerjee R, Johnston B, Lohse C, et al. The clonal distribution and diversity of extraintestinal Escherichia coli isolates vary according to patient characteristics. Antimicrob Agents Chemother 2013; 57: 5912-7
34. Willemsen I, Nelson J, Hendriks Y, et al. Extensive Dissemination of Extended Spectrum β-Lactamase-Producing Enterobacteriaceae in a Dutch Nursing Home. Infect Control Hosp Epidemiol 2015; 36: 394-400
35. Miajlovic H, Smith SG. Bacterial self-defence: how Escherichia coli evades serum killing. FEMS Microbiol Lett 2014; 354: 1-9
36. Henriksen AZ, Maeland JA. Serum antibodies to outer membrane proteins of Escherichia coli in healthy persons and patients with bacteremia. J Clin Microbiol 1987; 25: 2181-8
37. Kaijser B, Ahlstedt S. Protective capacity of antibodies against Escherichia coli and K antigens. Infect Immun 1977; 17: 286-9
38. Cross AS, Gemski P, Sadoff JC, Orskov F, Orskov I. The importance of the K1 capsule in invasive infections caused by Escherichia coli. J Infect Dis 1984; 149: 184-93
39. Cross AS, Sadoff JC, Furer E, Cryz SJ. Escherichia coli and Klebsiella vaccines and immunotherapy. Infect Dis Clin North Am 1990; 4: 271-82
40. Söderström T, Hansson G, Larson G. The Escherichia coli K1 capsule shares antigenic determinants with the human gangliosides GM3 and GD3. N Engl J Med 1984; 310: 726-7
41. Orskov I, Orskov F. Escherichia coli in extra-intestinal infections. J Hyg (Lond) 1985; 95: 551-75
42. Cryz SJ, Cross AS, Sadoff JC, Wegmann A, Que JU, Fürer E. Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans. J Infect Dis 1991; 163: 1040-5
43. Feldman MF, Wacker M, Hernandez M, et al. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA 2005; 102: 3016-21
44. Ihssen J, Kowarik M, Dilettoso S, Tanner C, Wacker M, Thöny-Meyer L. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Factories 2010; 9: 61
45. Lee CJ. Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry. Biol J Int Assoc Biol Stand 2002; 30: 97-103
46. Nurkka A, Lahdenkari M, Palmu AA, Käyhty H, FinOM Study Group. Salivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial. BMC Infect Dis 2005; 5: 41
47. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-8
48. Fattom A, Cho YH, Chu C, Fuller S, Fries L, Naso R. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 1999; 17: 126-33
49. Dagan R, Poolman J, Siegrist C-A. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010; 28: 5513-23